Drug Development

Feliza Mirasol is the science editor for 

Articles

Newly launched Crossbow Therapeutics will work to advance a novel class of antibody therapies for treating cancers.

Crossbow Therapeutics Debuts with $80 Million in Series A Financing to Advance Antibody Therapeutics

Chime Biologics, Leads Biolabs, and BeiGene have formed a three-way collaboration to advance the development and global manufacturing of Leads Biolabs’ lead mAb candidate, LBL-007.

Chime Biologics Forms mAb Development and Manufacturing Deal with Leads Biolabs and BeiGene

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Sample dilution, sensitivity, excipient interference, and containment are key issues that must be addressed.

Overcoming Analytical Challenges in High Potency Formulation

Felicity Thomas is the former Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Aenova has opened a new building for the production of highly potent APIs in Germany.

Aenova Opens New Building for Highly Potent Drugs

The new excipients manufacturing facility is expected to be completed in 2025.

Croda Pharma Breaks Ground on Excipients Manufacturing Facility

invoX Pharma has made a second tranche of investment in pHion Therapeutics to support further development of next-generation mRNA vaccines.

invoX Pharma Invests in pHion Therapeutics to Develop Next-Generation mRNA Vaccines

Nanotech-based delivery technologies are receiving significant attention.

Overcoming the Poor Solubility of Cannabinoids

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

An increase in applications for gene therapies is putting stress on FDA’s resources.

FDA Eyes New Strategies to Spur Gene Therapy Development

The start of production of US engineering batches of NXC-201, a CAR-T cell therapy candidate in early clinical development, is the first step in transferring Nexcella’s existing manufacturing process to the United States.

Nexcella Begins Production of CAR-T Cell Therapy Engineering Batches at US Manufacturing Site

Sandoz’s marketing authorization applications for a proposed biosimilar to denosumab are supported by a comprehensive analytical and clinical data package.

APIs and Excipients